Brevity: A Phase II Study of Brentuximab vedotin (SGN-35) using a response adapted design in patients with Hodgkin Lymphoma unsuitable for chemotherapy due to age, fraility or co-morbidity

  • Fenwick, Nicola (Principal Investigator)
  • Siddique, Shamyla (Co-Investigator)

Project Details

Short titleBrevity: A Phase II Study of Brentuximab vedotin (SGN-35) using a response adapted design in patients with Hodgkin Lymphoma unsuitable for chemotherapy due to age, fraility or co-morbidity
StatusFinished
Effective start/end date5/02/14 → 30/06/21

Funding

  • MILLENNIUM PHARMACEUTICALS INC